Shire Wins Patent Trial Against Watson Concerning LIALDA®

Lexington, Massachusetts (ots/PRNewswire) -

LIALDA Patent Upheld and Extends through June 8, 2020

Shire plc (LSE: SHP, NASDAQ: SHPG) and its subsidiary, Shire
Development LLC, announced today that the United States District
Court for Southern Florida has upheld its patent for LIALDA®
(mesalamine) delayed release tablets for the induction of remission
in adults with active, mild to moderate ulcerative colitis and for
the maintenance of remission of ulcerative colitis.

The decision follows litigation by Shire against Watson
Pharmaceuticals Inc., Watson Laboratories, Inc.-Florida, Watson
Pharma, Inc. and Watson Laboratories, Inc. (collectively "Watson",
now "Actavis") in connection with their Abbreviated New Drug
Application ("ANDA") for a generic version of LIALDA.

Judge Donald M. Middlebrooks issued a ruling holding that Actavis'
proposed ANDA formulation infringes US Patent No. 6,773,720 ("'720
patent"), the Orange Book listed patent for LIALDA, which extends
through June 8, 2020. Accordingly, Judge Middlebrooks entered an
injunction prohibiting the FDA from approving the ANDA formulation
until the expiration of the '720 patent and an injunction against
Actavis prohibiting them from making, using, selling or importing
their proposed ANDA product until after the expiration of the '720
patent. This is the second patent infringement trial in which the
proposed ANDA product from Actavis (formerly Watson) has been found
to infringe the '720 patent.

"Shire is very pleased that the court has once again ruled in our
favour, reaffirming the validity of the patent protecting LIALDA,"
said James Harrington, Senior Vice President, Global Head of
Intellectual Property, Shire. "This ruling supports the innovation
and value we continue to bring to the patients who benefit from this
important medicine that allows them to lead better lives."

Shire's LIALDA remains the only once-daily mesalamine product
indicated for both the induction of remission of mild to moderate
ulcerative colitis and the maintenance of remission of ulcerative
colitis.

Indication

Lialda is a prescription medication approved for the induction of
remission in patients with active, mild to moderate ulcerative
colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

Do not take Lialda (mesalamine) if you are allergic to
salicylates, such as aspirin, or medications that contain aspirin;
aminosalicylates; mesalamine; or any other ingredients in Lialda.

Tell your doctor if you:

- have or have had kidney problems. Kidney problems have been
reported with medications that contain mesalamine, such as Lialda.
Your doctor may check to see how your kidneys are working before
starting Lialda and periodically while taking Lialda.
- have symptoms including cramping, stomach ache, bloody diarrhea,
fever, headache, and rash. Medications that contain mesalamine,
such as Lialda, have been associated with a condition that may be
hard to tell apart from a UC flare. Call your doctor right away if
you have any of these symptoms. He or she may tell you to stop
taking Lialda.
- are allergic to sulfasalazine, as you may also be allergic to
Lialda or medications that contain mesalamine.
- have or have had heart-related allergic reactions, such as
inflammation of the heart muscle (myocarditis) or the lining of the
heart (pericarditis). These reactions have been seen in patients
taking Lialda or medications that contain mesalamine. Your chance
of having these types of reactions may increase when taking Lialda.
- have or have had liver problems. Problems with liver function have
been reported in patients who have or have had liver problems and
were taking medications that contain mesalamine, such as Lialda.
- have a stomach blockage. It may take longer for Lialda to start
working.

The most common side effects reported in clinical studies of
Lialda were:

- ulcerative colitis
- headache
- passing gas
- abnormal liver function test results
- stomach ache

In clinical studies of Lialda, inflammation of the pancreas also
occurred. If this happens to you, your doctor may tell you to stop
taking Lialda.

Other side effects may occur.

Before starting Lialda, tell your doctor about all medications you
are taking, including:

- non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen
and naproxen. Taking these medications with Lialda may increase
your chance of kidney problems.
- azathioprine and 6-mercaptopurine. Taking these medications with
Lialda may increase your chance of blood disorders.

Please see Full Prescribing Information
(http://pi.shirecontent.com/?product=LIALDA&country=USA&language=ENG)
for Lialda (mesalamine)

You are encouraged to report negative side effects of prescription
drugs to the FDA.

Visit http://www.FDA.gov/medwatch, or call 1-800-FDA-1088.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better
lives.

Our strategy is to focus on developing and marketing innovative
specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience,
Gastrointestinal and Internal Medicine and we are developing
treatments for symptomatic conditions treated by specialist
physicians in other targeted therapeutic areas, such as Ophthalmics.

http://www.shire.com

Forward-Looking Statements

Statements included herein that are not historical facts,
including without limitation statements concerning our announced
business combination with Baxalta and the timing and financial and
strategic benefits thereof, our 20x20 ambition that targets $20
billion in combined product sales by 2020, as well as other targets
for future financial results, capital structure, performance and
sustainability of the combined company, the combined company's future
strategy, plans, objectives, expectations and intentions, the
anticipated timing of clinical trials and approvals for, and the
commercial potential of, inline or pipeline products are
forward-looking statements. Such forward-looking statements involve a
number of risks and uncertainties and are subject to change at any
time. In the event such risks or uncertainties materialize, Shire's
results could be materially adversely affected. The risks and
uncertainties include, but are not limited to, the following:

- the proposed combination with Baxalta may not be completed due to a
failure to satisfy certain closing conditions, including any
shareholder or regulatory approvals or the receipt of applicable
tax opinions;
- disruption from the proposed transaction with Baxalta may make it
more difficult to conduct business as usual or maintain
relationships with patients, physicians, employees or suppliers;
- the combined company may not achieve some or all of the anticipated
benefits of Baxalta's spin-off from Baxter International, Inc.
("Baxter") and the proposed transaction may have an adverse impact
on Baxalta's existing arrangements with Baxter, including those
related to transition, manufacturing and supply services and tax
matters;
- the failure to achieve the strategic objectives with respect to the
proposed combination with Baxalta may adversely affect the combined
company's financial condition and results of operations;
- products and product candidates may not achieve commercial success;
- product sales from ADDERALL XR and INTUNIV are subject to generic
competition;
- the failure to obtain and maintain reimbursement, or an adequate
level of reimbursement, by third-party payers in a timely manner
for the combined company's products may affect future revenues,
financial condition and results of operations, particularly if
there is pressure on pricing of products to treat rare diseases;
- supply chain or manufacturing disruptions may result in declines in
revenue for affected products and commercial traction from
competitors; regulatory actions associated with product approvals
or changes to manufacturing sites, ingredients or manufacturing
processes could lead to significant delays, an increase in
operating costs, lost product sales, an interruption of research
activities or the delay of new product launches;
- the successful development of products in various stages of
research and development is highly uncertain and requires
significant expenditures and time, and there is no guarantee that
these products will receive regulatory approval;
- the actions of certain customers could affect the combined
company's ability to sell or market products profitably, and
fluctuations in buying or distribution patterns by such customers
can adversely affect the combined company's revenues, financial
condition or results of operations;
- investigations or enforcement action by regulatory authorities or
law enforcement agencies relating to the combined company's
activities in the highly regulated markets in which it operates may
result in significant legal costs and the payment of substantial
compensation or fines;
- adverse outcomes in legal matters and other disputes, including the
combined company's ability to enforce and defend patents and other
intellectual property rights required for its business, could have
a material adverse effect on the combined company's revenues,
financial condition or results of operations;
- Shire is undergoing a corporate reorganization and was the subject
of an unsuccessful acquisition proposal and the consequent
uncertainty could adversely affect the combined company's ability
to attract and/or retain the highly skilled personnel needed to
meet its strategic objectives;
- failure to achieve the strategic objectives with respect to Shire's
acquisition of NPS Pharmaceuticals Inc. or Dyax may adversely
affect the combined company's financial condition and results of
operations;
- the combined company will be dependent on information technology
and its systems and infrastructure face certain risks, including
from service disruptions, the loss of sensitive or confidential
information, cyber-attacks and other security breaches or data
leakages that could have a material adverse effect on the combined
company's revenues, financial condition or results of operations;
- the combined company may be unable to retain and hire key personnel
and/or maintain its relationships with customers, suppliers and
other business partners;
- difficulties in integrating Dyax or Baxalta into Shire may lead to
the combined company not being able to realize the expected
operating efficiencies, cost savings, revenue enhancements,
synergies or other benefits at the time anticipated or at all; and
other risks and uncertainties detailed from time to time in
Shire's, Dyax's or Baxalta's filings with the Securities and
Exchange Commission ("SEC"), including those risks outlined in
Baxalta's current Registration Statement on Form S-1, as amended,
and in "ITEM 1A: Risk Factors" in Shire's Annual Report on Form
10-K for the year ended December 31, 2015.

All forward-looking statements attributable to us or any person
acting on our behalf are expressly qualified in their entirety by
this cautionary statement. Readers are cautioned not to place undue
reliance on these forward-looking statements that speak only as of
the date hereof. Except to the extent otherwise required by
applicable law, we do not undertake any obligation to republish
revised forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events.

ots Originaltext: Shire Pharmaceuticals Group Plc
Im Internet recherchierbar: http://www.presseportal.de

Contact:
please contact:
Investor Relations
Sarah Elton-Farr,seltonfarr@shire.com , +44(0)1256-894157
Robert Coates,rcoates@shire.com , +44(0)1256-894874
Media
Michele Galen, mgalen@shire.com , +1-781-482-1867
Gwen Fisher,gfisher@shire.com , +1-484-595-9836
Brooke Clarke, brclarke@shire.com , +44(0)1256-894829